Two Onc Docs Chronic Lymphocytic Leukemia (CLL)
Dec 12, 2022
Dive into the world of Chronic Lymphocytic Leukemia (CLL), where you'll learn about its often asymptomatic nature, especially in older adults. Discover the vital role of flow cytometry in accurate diagnosis and the significance of chromosomal abnormalities in prognosis. Explore treatment strategies, including the use of BTK inhibitors and combination therapies. Tune in for insights on managing complications and approaches for relapsed cases that take patient prognosis into account.
AI Snips
Chapters
Transcript
Episode notes
Key Flow Cytometry Markers
- CLL diagnosis often involves detecting specific markers with flow cytometry: positive CD19, dim CD20, positive CD23, and CD5.
- Mantle cell lymphoma also has CD5 positive but differs by CD23 negativity, helping distinguish between these diseases.
CLL Prognostic Factors
- Prognostic factors in CLL include chromosomal abnormalities and IGHV mutation status, which remains stable over time.
- Good prognosis markers: 13q deletion, trisomy 12, mutated IGHV; bad prognosis markers: deletion 17P, 11Q, unmutated IGHV, positive ZAP70 and CD38.
When to Treat CLL
- Treat CLL patients only when symptomatic with B symptoms, bulky disease, or threatened organ function.
- Asymptomatic patients can be safely managed with surveillance without immediate treatment.